

ERRATUM

Open Access



Erratum to: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models

Giovanni Luca Gravina¹, Andrea Mancini¹, Patrizia Sanita¹, Flora Vitale¹, Francesco Marampon¹, Luca Ventura², Yosef Landesman³, Dilara McCauley³, Michael Kauffman³, Sharon Shacham³ and Claudio Festuccia^{1*}

Unfortunately, the original version of this article [1] contained a mistake. The word 'survivin' in the title was incorrectly included as 'surviving'. The title has been corrected above and in the original article.

Author details

¹Department of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, L'Aquila, Italy. ²Pathology Division, San Salvatore Hospital, L'Aquila, Italy. ³Karyopharm Therapeutics, Newton, MA, USA.

Received: 21 December 2015 Accepted: 21 December 2015

Published online: 11 January 2016

Reference

1. Gravina G, Mancini A, Sanita P, Vitale F, Marampon F, Ventura L. KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models. *BMC Cancer*. 2015;15:941.

* Correspondence: claudio.festuccia@univaq.it

¹Department of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, L'Aquila, Italy
Full list of author information is available at the end of the article

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

